Table 3. Geometric mean pneumococcal polysaccharide antibody concentrations in vaccinated and control villages following vaccination with 1 dose of PCV-7 or serogroup C meningococcal conjugate vaccine (data from CSS1–CSS3 combined).

	30 months –4 years					5 years+
Serotypes	Control	Vacc	Ratio	Ratio adj†	P value	Control	Vacc	Ratio	Ratio adj†	P value	P value int‡
PCV-7
4	0.42	0.60	1.44	1.46(0.19,11.34)	0.694	0.77	1.99	2.58	2.53(1.04,6.20)	0.042	0.431
6B	0.61	2.28	3.72	3.73(1.09,12.85)	0.038	1.76	2.91	1.66	1.66(0.68,4.03)	0.247	0.190
9V	0.54	1.38	2.55	2.20(0.77,6.29)	0.130	1.97	2.53	1.29	1.09(0.47,2.52)	0.836	0.173
14	0.67	3.73	5.58	3.98(0.98,16.21)	0.053	2.69	4.64	1.72	1.72(0.64,4.66)	0.264	0.022
18C	0.39	0.70	1.77	2.70(1.14,6.37)	0.027	1.04	2.80	2.70	2.63(1.11,6.22)	0.030	0.305
19F	2.14	2.33	1.09	1.36(0.57,3.26)	0.463	3.58	5.24	1.46	1.46(0.78,2.72)	0.220	0.816
23F	0.24	0.8	3.40	2.33(0.57,9.54)	0.219	1.01	0.70	0.69	0.67(0.22,2.04)	0.458	0.080
Non-PCV-7
1	0.48	0.35	0.72	0.64(0.20,2.00)	0.408	1.01	0.99	0.98	0.93(0.45,1.90)	0.825	0.767
3	0.45	0.74	1.62	1.51(0.25,8.97)	0.626	0.47	0.72	1.53	1.57(0.68,3.62)	0.268	0.749
5	1.40	0.88	0.62	0.62(0.21,1.88)	0.370	2.06	1.85	0.9	0.99(0.56,1.75)	0.958	0.248
12F	0.73	0.44	0.61	0.53(0.17,1.68)	0.255	1.19	0.97	0.81	0.80(0.36,1.78)	0.570	0.253

Due to similar kinetics in response to a single dose of PCV-7 at the three times points of assessment, data from CSS1 to CSS3 were combined to increase study power. The ratio of the GM in the vaccinated and control communities are derived and adjusted for the baseline values (†).

^‡indicate the p-values for test for a difference in the effect of vaccine in the two age groups (interaction).